Dova Pharmaceuticals Inc

Dova Pharmaceuticals — Technical Presentation (October 2017)

24 slides from Dova Pharmaceuticals's technical presentation, Oct 23, 2017

  1. Slide 1: Disclaimer

    Disclaimer This presentation contains forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Dova’s current beliefs, expectations and assumptions regarding the future of Dova’s business, future plans and st

  2. Slide 2: Dr. Lee Allen, CMO: Introduction

    Dr. Lee Allen, CMO: Introduction Avatrombopag is an orally administered thrombopoietin receptor agonist that mimics the effects of endogenous thrombopoietin leading to the production of platelets Two completed pivotal Phase 3 clinical trials, ADAPT-1 and ADAPT-2, evaluated avatrombopag for the treat

  3. Slide 3: Dr. Norah Terrault: Bio

    Professor of Medicine at the University of California San Francisco, Division of Gastroenterology, and the Principal Investigator of our ADAPT-1 and ADAPT-2 clinical trials Nationally and internationally recognized for her work related to viral hepatitis in the setting of liver transplantation Autho

  4. Slide 4: Superiority of Avatrombopag to Placebo in Chronic Liver Disease-Associated Thrombocytopenia

    Superiority of Avatrombopag to Placebo for the Treatment of Chronic Liver Disease-Associated Thrombocytopenia in Patients Undergoing Scheduled Procedures: Results of 2 Randomized, Placebo-Controlled Phase 3 Studies ADAPT-1 and ADAPT-2 Norah Terrault1, Francesco Bibbiani2, Yi-Cheng Chen3, Namiki Izum

  5. Slide 5: Thrombocytopenia and Chronic Liver Disease

    Thrombocytopenia and Chronic Liver Disease Severe thrombocytopenia (platelet count <50 x 109/L) is common in patients chronic liver disease Platelet transfusions are current standard of care to reduce risk of bleeding during invasive procedures with Associated with risk refractoriness pharmacologica

  6. Slide 6: Avatrombopag Phase 3 Studies - ADAPT-1 & ADAPT-2

    Avatrombopag Phase 3 Studies-ADAPT-1 & ADAPT-2 Two global Phase III studies of avatrombopag in patients with thrombocytopenia and chronic liver disease undergoing scheduled procedures Identically-designed, randomized, double-blind, placebo-controlled, parallel-group studies In total, 435 patients re

  7. Slide 7: Avatrombopag Phase 3 Study Design

    Avatrombopag Phase 3 Study Design ADAPT-1 & ADAPT-2 *Platelet transfusions were not mandatory Low Baseline Platelet Count Cohort R 2:1 High Baseline Platelet Count Cohort R 2:1 8 PLACEBO mean Baseline PC 40 to <50 X 109/L 40 MG AVATROMBOPAG qd x 5 Days PLACEBO mean Baseline PC <40 X 109/L 60 MG AVAT

  8. Slide 8: Study Population Criteria ADAPT-1 & ADAPT-2

    Avatrombopag Phase 3 Study Population Criteria ADAPT-1 & ADAPT-2 disorders, or cardiovascular disease syndromes agents within 7 days of screening (females) *Platelet counts were measured on 2 separate occasions: During the Screening Period and at Baseline at least 1 day apart with neither platelet c

  9. Slide 9: Outcome Measures

    ADAPT-1 & ADAPT-2: Outcome Measures PRIMARY EFFICACY ENDPOINT: SECONDARY EFFICACY ENDPOINTS: SAFETY ENDPOINTS: 10 Adverse events, serious adverse events, Adverse Events of Special Interest (AESI) Proportion of patients achieving the target platelet count (>50 x 109/L) Magnitude of change in platelet

  10. Slide 10: Subject Disposition

    ADAPT-1 & ADAPT-2: Subject Disposition 11 Subjects Enrolled ADAPT-1 (N=370) ADAPT-2 (N=346) Subjects Randomized ADAPT-1 (N=231) ADAPT-2 (N=204) Low Baseline Platelet Count Cohort <40 X 109/L High Baseline Platelet Count Cohort 40 to <50 X 109/L PLACEBO 60 MG AVATROMBOPAG PLACEBO 40 MG AVATROMBOPAG A

  11. Slide 11: Patient Demographics

    ADAPT-1 & ADAPT-2: Patient Demographics Race 12 White58% 58% 56% 54% 63% 57% 75% 69% Asian38% 37% 44% 42% 23% 36% 25% 21% Other4% 5% 0 4% 14% 7% 0 10% ADAPT-1 ADAPT-2 Low Baseline PlateletHigh Baseline Platelet Count CohortCount Cohort <40 x 109/L 40 to <50 x 109/L Low Baseline PlateletHigh Baseline

  12. Slide 12: ADAPT-1 & ADAPT-2: Disease Characteristics

    APAPT-1 & ADAPT-2: Disease Characteristics 13 ADAPT-1 ADAPT-2 Low Baseline PlateletHigh Baseline Platelet Count CohortCount Cohort <40 x 109/L 40 to <50 x 109/L Low Baseline PlateletHigh Baseline Platelet Count CohortCount Cohort <40 x 109/L 40 to <50 x 109/L Placebo (n=48) Avatrombopag 60 mg (n=90)

  13. Slide 13: Scheduled Procedures by Bleeding Risk

    ADAPT-1 & ADAPT-2: Scheduled Procedures by Bleeding Risk Count Cohort Count Cohort Upper GI endoscopy +/-biopsy 14 Low Bleeding Risk Procedures Thoracentesis Paracentesis Endoscopy Upper GI endoscopy +/-variceal banding, +/-sclerotherapy Colonoscopy +/-polypectomy/biopsy Moderate Bleeding Risk Proce

  14. Slide 14: Primary Endpoint: Proportion Not Requiring Platelet Transfusion or Rescue

    ADAPT-1 & ADAPT-2: Primary Endpoint Proportion of Patients Who Did NOT Require Platelet Transfusion or Any Low Baseline Platelet Count Cohort <40 x 109/L Rescue Procedure for Bleeding* High Baseline Platelet Count Cohort 40 to <50 x 109/L 100 90 80 70 60 50 40 30 20 10 *Full Analysis Set 0 15 ADAPT-

  15. Slide 15: Secondary Endpoint: Platelet Counts >50 x 10^9/L

    ADAPT-1 & ADAPT-2: Secondary Endpoint Proportion of Patients Who Achieved Platelet Counts > 50 x 109/L Low Baseline Platelet Count Cohort <40 x 109/L on Procedure Day* High Baseline Platelet Count Cohort 40 to <50 x 109/L 100 90 80 70 60 50 40 30 20 10 0 *Full Analysis Set 16 ADAPT-1 ADAPT-2 ADAPT-1

  16. Slide 16: Secondary Endpoint: Change in Platelet Count

    ADAPT-1 & ADAPT-2: Secondary Endpoint Magnitude of Change in Platelet Count from Baseline to Procedure Day* Low Baseline Platelet Count Cohort <40 x 109/L High Baseline Platelet Count Cohort 40 to <50 x 109/L 50 45 40 35 30 25 20 15 10 5 *Full Analysis Set #Hodges-Lehmann Estimator 0 17 ADAPT-1 ADAP

  17. Slide 17: Change in Platelet Count Over Time

    ADAPT-1 & ADAPT-2: Change in Platelet Count Over Time Platelet counts reproducibly increased from Day 4, peaked at Day 10-13, and returned to Baseline levels by Day 35 Only 3 (1.1%) avatrombopag-treated patients had platelet counts >200 x109/L at any time during the study ADAPT-1 ADAPT-2 100 100 90

  18. Slide 18: Combined Safety Analysis: Most Frequent Adverse Events

    Combined ADAPT-1 & ADAPT-2-Safety Analysis Set Most Frequently Reported TE-Emergent Adverse Events Platelet Count Cohort Safety Analysis Set-defined as all randomized subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment; Treatment-emergent Adverse Event (

  19. Slide 19: Combined Safety Analysis: Treatment-Emergent Adverse Events

    Combined Treatment ADAPT-1 & ADAPT-2-Safety Analysis Set Emergent Adverse Events Platelet Count Cohort Safety Analysis Set-defined as all randomized subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment; Treatment-emergent Adverse Event (TEAE) an adverse e

  20. Slide 20: Deaths & Adverse Events Leading to Discontinuation

    ADAPT-1 & ADAPT-2: Deaths & Adverse Events Leading to Discontinuation TEAEs Leading to Study Drug Discontinuation N=2 (1.3%) in ADAPT-1 both in the 60 mg Avatrombopag Myalgia and anemia; possibly study drug-related Pyrexia; unrelated to study drug Treatment Group Deaths N=2 (1.7%) in ADAPT-1 both in

  21. Slide 21: Adverse Events of Special Interest

    ADAPT-1 & ADAPT-2: Adverse Events of Special Interest Medically Significant Events N=1 (0.4% in avatrombopag-exposed) TEAE of partial portal vein thrombosis 71 yo male in the 40 mg Avatrombopag treatment group on Study Day 18 (Visit 5), 13 days after the last dose Scheduled Procedure: Upper gastroin

  22. Slide 22: Summary and Conclusions

    Summary and Conclusions Avatrombopag was superior to placebo in: Reducing the need for platelet transfusion or any rescue procedure for bleeding following a scheduled procedure Increasing the proportion of patients achieving the target platelet count (>50 x 109/L) Increasing the platelet count from

  23. Slide 23: Summary and Conclusions

    Summary and Conclusions e Avatrombopag was superior to placebo in: e Reducing the need for platelet transfusion or any rescue procedure for bleeding following a scheduled procedure e Increasing the proportion of patients achieving the target platelet count (250 x 109/L) e Increasing the platelet cou

  24. Slide 24: Questions & Answers

    Questions & Answers

Dova Pharmaceuticals — Technical Presentation (October 2017) on 6ix